Kristen HollingerInvestigator: Dr. Kristen Hollinger

Disease: Pediatric Depression

Research Description: Suicide due to major depressive disorder (MDD) has simultaneously become a leading cause of death around the world (particularly among children, adolescents and young adults) and a growing silent epidemic for which we have made little to no progress for decades. The current standard of care for severe MDD includes antidepressant drug treatment, such as a selective serotonin reuptake inhibitor (SSRI), often in combination with cognitive behavioral therapy. It takes approximately 4 weeks for SSRIs to produce mood-lifting effects, and during that time, particularly in pediatric populations, an increase in suicidal behaviors can be seen. Our research suggests that a rapid drop in serotonin release during acute exposure to antidepressant treatment could account for this increase in suicidal behaviors. To overcome the initial drop in serotonin, we propose the use of repurposed drugs, pindolol and buspirone, to be delivered in combination with a SSRI antidepressant for the first month of treatment. Pindolol and buspirone block a specific serotonergic receptor in the brain, thereby allowing more serotonin to be released during acute antidepressant treatment. This combination has the potential to prevent suicidal behaviors following SSRI treatment. Preclinical studies in mice will evaluate the efficacy and appropriate doses of pindolol or buspirone to be translated to human studies.

CWR funding role: Primary funder

Start date: December 2016

Most recent report: Tests of different doses of pindolol or buspirone plus an SSRI in mice will begin in late 2016.

Anticipated next steps:

→ Data published in a scientific journal and/or presented at a scientific conference

→ Pre-clinical findings lead to human clinical trial

→ Data leveraged into larger philanthropic or government funding for this treatment


Sign up for our eNewsletter today!


First Name

Cures Within Reach



Tuesday the 16th. copyright 2015 Cures Within Reach.